Association of SLC polymorphism with histology and overall survival
We further assessed the role of SLC variants in predicting median survival of lung carcinoma patients based on histological subtypes. On analysis, we noted that ADCC patients harboring mutant genotype (AA ) showed better survival outcomes compared to the ADCC subjects with wild-type genotype (GG ) for SLC19A1 G80A (MST=9.4 versus 8.8,Log-rank p=0.2) as shown inTable 4 . After applying the cox regression model, there was a decreased hazard ratio for lung cancer patients (HR1=0.60, 95%CI=0.36-1.00, p=0.04 ).
For SLCO1B1 A388G , patients diagnosed with SQCC and harboring the mutant genotype (GG ) showed poor survival outcomes when compared to combined wild type and heterozygous genotype (AA+AG ) (MST=6.8 months versus 7.5 months; log-rank p=0.42). After multivariate analysis, the overall death risk of patients carryingGG genotype at A388G was 1.54 times higher than individuals with AA+AG genotype (HR=1.54, 95% CI=0.99-2.39; p=0.05) . However, on analyzing the association ofSLC19A1 G80A polymorphism with SCLC histology, our results depicted increased survival in the patients harboring mutant genotype (AA ) as compared to the SCLC subjects having wild type genotype (GG ) (MST=9.6 months versus 7.6 months, p=0.34). After multivariate analysis, such patients had a low death ratio than SCLC subjects carrying the wild genotype (GG ) (HR=0.22, 95%CI=0.05-0.93, p=0.04, Table 4, Figure 4 ). Similar results were also obtained when the recessive model was applied (HR=0.30, 95%CI=0.11-0.84, p=0.02) .None of the other SCLC patients showed prognostic significance for the SLCO1B1 A388G, T521C, and SLCO1B3 A1683-5676G polymorphism (Supplementary Table 1).